The rising interest in potent weight management has led to considerable investigation into cutting-edge treatments. Currently, Retatrutide, a dual -action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist , has demonstrated promising check here results in patient trials, indicating potential for